HealO Homepage

Type 1 Diabetes: The Glycemic Control Crisis & The Case for Precision

https://www.choa.org/-/media/Images/Childrens/global/social-share-images/parent-resources/diabetes/child-girl-checking-blood-sugar-1200x630.jpg

Type 1 diabetes is not just about taking insulin.

It is about how much glucose circulates in the bloodstream — every hour, every day, for decades.

Despite modern tools like pumps and CGMs, average HbA1c globally remains high. And that chronic elevation quietly drives long-term damage.

This is the conversation most families are not having clearly enough.

The Glycemic Control Reality

Large registry data — including cohorts from the T1D Exchange — show average HbA1c levels around 8% in many populations.

An HbA1c of 8% corresponds to an average glucose of approximately 183 mg/dL (10.2 mmol/L).

For context:

• Normal average glucose ≈ 83–100 mg/dL
• Many T1D patients live 60–100 mg/dL above physiologic levels
• Daily swings of 50–60 mg/dL are common

Globally, a significant proportion of individuals with T1D fall in the 7.5–9% HbA1c range.

Children and adolescents often have the highest averages due to growth hormones, puberty-related insulin resistance, and behavioral factors.

This is not a failure of families.

It is a structural problem in how we approach management.

Why HbA1c Matters So Much

The landmark Diabetes Control and Complications Trial and its follow-up Epidemiology of Diabetes Interventions and Complications demonstrated a powerful truth:

Every ~10% reduction in HbA1c significantly reduces risk of microvascular complications.

Lower HbA1c was associated with:

• Reduced retinopathy progression
• Reduced nephropathy
• Reduced neuropathy

Glucose exposure is dose-dependent toxicity.

Chronic hyperglycemia generates:

• Oxidative stress
• Advanced glycation end-products (AGEs)
• Endothelial dysfunction
• Microvascular damage

Over decades, this accumulates.

Mortality & Long-Term Risk

Population-based cohorts such as those led by Araz Rawshani and Shona Livingstone demonstrate sobering trends:

• All-cause mortality several-fold higher than general population
• Markedly increased cardiovascular disease risk
• Shortened life expectancy — particularly with early-onset T1D

Cardiovascular disease remains a leading cause of death.

Chronic kidney disease risk rises with persistent hyperglycemia.

Retinopathy affects a large proportion of long-standing cases.

These outcomes correlate strongly with glucose exposure over time.

The Tool Gap: Why Technology Alone Hasn’t Solved It

ToolTypical HbA1c ReductionLimitation
Carb countingModestStill large glucose loads
Insulin pumps~0.3%Reactive dosing
CGMImproves trendsDoes not reduce carb load
Hybrid closed-loop~0.5–0.6%Often targets 130–180 mg/dL
Islet transplantTemporary normalizationRejection, immunosuppression

Technology improves safety and reduces hypoglycemia risk.

But most systems are designed around:

Managing high carbohydrate intake safely — not eliminating the glycemic load itself.

Even modern closed-loop systems often target glucose ranges well above physiologic fasting levels.

The result?

Better — but not normal.

The Variability Problem

https://glucosensor.com/nhws-content/uploads/2025/02/Big-swings-curve.jpg
https://media-cldnry.s-nbcnews.com/image/upload/newscms/2019_36/1479157/hypoglycemia-signs-illustration-today-inline-190906-03.jpg
https://cdn.prod.website-files.com/588f9278c498fd3f484e74c7/5910b73eeb95fc348ca16a7b_Glycemia.svg
High carbohydrate intake increases:

• Insulin dosing size
• Margin of dosing error
• Post-meal spikes
• Hypoglycemia risk from overcorrection

Large doses → larger mistakes.

Smaller doses → smaller consequences.

This principle is sometimes referred to as the “law of small numbers.”

Glucose variability itself may independently contribute to oxidative stress beyond mean glucose alone.

The Low-Carbohydrate Argument

Some clinicians — notably Richard K. Bernstein — advocate very-low-carbohydrate strategies (<30g/day) to minimize glucose excursions.

Reported outcomes in adherent individuals include:

• Lower HbA1c (sometimes near non-diabetic range)
• Reduced glycemic variability
• Fewer severe hypoglycemia episodes
• Improved time-in-range

The core logic:

Less carbohydrate →
Less insulin required →
Less variability →
Lower oxidative burden →
Lower complication risk.

However, critical caveats:

• Requires low-carb physician supervision/ self training
• Must ensure adequate nutrition (especially in children)
• Growth monitoring is essential
• Psychological sustainability matters
• Individualization is non-negotiable

This is not a casual dietary shift.

It is a structured metabolic strategy.

A HealO Perspective for T1D Families

In Pakistan, access to pumps and closed-loop systems is limited by cost.

CGMs are improving access but remain expensive.

Diet, however, is modifiable.

Reducing refined carbohydrates — white rice overload, roti stacking, sugary drinks — can dramatically reduce post-meal spikes.

Even moderate carbohydrate reduction can:

• Improve time-in-range
• Lower insulin requirements
• Reduce variability
• Ease daily management burden

The goal is not perfection.

The goal is stability.

What Truly Determines Long-Term Outcome?

Not the brand of pump.
Not the insulin type alone.
Not the technology dashboard.

But:

• Average glucose exposure
• Variability
• Years spent above physiologic levels

Duration × Degree of Hyperglycemia = Complication Risk

That equation has not changed in 100 years.

Final Message to Parents

Your child’s diagnosis is not their destiny.

But chronic high glucose is not benign.

Technology helps.

Education empowers.

Precision protects.

Lowering HbA1c safely — while minimizing variability — is the most powerful lever available today.

Whether through structured carb reduction, advanced tech, or a combination:

The objective remains the same:

Normalize glucose as closely and safely as possible — for decades.

That is how lifespan is reclaimed.

References
  1. https://diatribe.org/understanding-diabetes/can-people-type-1-diabetes-also-get-type-2
  2. https://www.sciencedirect.com/science/article/pii/S016882271630153X
  3. https://dom-pubs.onlinelibrary.wiley.com/doi/abs/10.1111/dom.13848
  4. https://www.sciencedirect.com/science/article/abs/pii/S1043276006002633
  5. https://www.scribd.com/document/920635243/Dr-Bernsteins-Diabetes-Solution
  6. https://archive.org/details/isbn_9780316182690
  7. https://www.youtube.com/channel/UCuJ11OJynsvHMsN48LG18Ag
  8. https://www.youtube.com/watch?v=dPd78PnsQNA
  9. https://www.youtube.com/watch?v=4X7IwzFPn_Q
  10. https://www.youtube.com/watch?v=qQc2H26T98E&t=469s
  11. https://www.youtube.com/watch?v=3xdlzHyysNk&t=7s
  12. https://www.youtube.com/watch?v=3xdlzHyysNk&list=PLs_TA02I6IvX_FakgvWkfziEciqRSgZnz
  13. https://www.youtube.com/watch?v=3PZno7Nkuuw
  14. https://www.youtube.com/watch?v=3xdlzHyysNk&t=7s
  15. https://www.youtube.com/watch?v=3xdlzHyysNk&list=PLs_TA02I6IvX_FakgvWkfziEciqRSgZnz
  16. https://www.youtube.com/watch?v=3PZno7Nkuuw
  17. https://www.youtube.com/watch?v=3xdlzHyysNk&t=7s
  18. https://www.youtube.com/watch?v=3xdlzHyysNk&list=PLs_TA02I6IvX_FakgvWkfziEciqRSgZnz
  19. https://www.youtube.com/watch?v=3PZno7Nkuuw
  20. https://www.youtube.com/watch?v=3xdlzHyysNk&t=7s
  21. https://www.youtube.com/watch?v=3xdlzHyysNk&list=PLs_TA02I6IvX_FakgvWkfziEciqRSgZnz
  22. https://www.youtube.com/watch?v=3PZno7Nkuuw
  23. https://www.youtube.com/watch?v=vyOI9bk3VZc
  24. https://www.youtube.com/watch?v=um0Ly12Wia8
  25. https://www.youtube.com/watch?v=zJGAbZIvRh8
  26. https://www.youtube.com/watch?v=GdmK_SCA2ls
  27. https://www.youtube.com/watch?v=fA1qh4Sty8g
  28. https://www.youtube.com/watch?v=zJGAbZIvRh8
  29. https://www.youtube.com/watch?v=Ho9-oD9KSiw
  30. https://www.youtube.com/watch?v=3PZno7Nkuuw
  31. https://professional.diabetes.org/diapro/glucose_calc
  32. https://t1dexchange.org/pages/
  33. http://care.diabetesjournals.org/content/39/12/e214
  34. https://jamanetwork.com/journals/jamaophthalmology/article-abstract/635006?redirect=true
  35. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3867999/
  36. https://www.ncbi.nlm.nih.gov/pubmed/9850487
  37. http://care.diabetesjournals.org/content/34/8/1843
  38. https://jamanetwork.com/journals/jama/fullarticle/2656808
  39. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31506-X/fulltext
  40. https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631
  41. https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685
  42. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31506-X/fulltext
  43. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  44. https://jamanetwork.com/journals/jama/fullarticle/2088852
  45. http://care.diabetesjournals.org/content/early/2016/05/14/dc15-2399
  46. https://www.nejm.org/doi/full/10.1056/NEJMoa1408214
  47. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31506-X/fulltext
  48. https://jamanetwork.com/journals/jama/fullarticle/2088852
  49. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  50. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3462745/
  51. https://www.ncbi.nlm.nih.gov/pubmed/16567818
  52. https://jamanetwork.com/journals/jama/fullarticle/2088852
  53. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4826427/
  54. https://jamanetwork.com/journals/jama/fullarticle/2088852
  55. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  56. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  57. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3217477/
  58. https://www.ncbi.nlm.nih.gov/pubmed/11956379
  59. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(18)31506-X/fulltext
  60. https://www.ncbi.nlm.nih.gov/pubmed/27925333
  61. https://jamanetwork.com/journals/jama/fullarticle/2088852
  62. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  63. https://www.alzheimersanddementia.com/article/S1552-5260(15)02297-9/abstract
  64. https://jamanetwork.com/journals/jama/fullarticle/2088852
  65. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  66. https://www.ncbi.nlm.nih.gov/pubmed/25767718
  67. https://jamanetwork.com/journals/jama/fullarticle/2088852
  68. https://www.ncbi.nlm.nih.gov/pubmed/29532512
  69. https://jamanetwork.com/journals/jama/fullarticle/2088852
  70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4138899/
  71. http://care.diabetesjournals.org/content/early/2015/07/01/dc15-0041
  72. https://www.sciencedirect.com/science/article/pii/S1056872718301090
  73. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5111534/
  74. https://www.ncbi.nlm.nih.gov/pubmed/29573221
  75. https://www.ncbi.nlm.nih.gov/pubmed/29654376
  76. https://www.ncbi.nlm.nih.gov/pubmed/26512024
  77. http://care.diabetesjournals.org/content/27/suppl_1/s84
  78. https://jamanetwork.com/journals/jamaophthalmology/article-abstract/635006?redirect=true
  79. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2761813/
  80. http://care.diabetesjournals.org/content/33/6/1315
  81. https://www.ncbi.nlm.nih.gov/pubmed/27889727
  82. https://www.ncbi.nlm.nih.gov/pubmed/24381884
  83. https://www.ncbi.nlm.nih.gov/pubmed/22361220
  84. https://www.ncbi.nlm.nih.gov/pubmed/22244464
  85. https://www.ncbi.nlm.nih.gov/pubmed/21051047
  86. http://lillydiabetes.com/_assets/pdf/hi86638_carbohydrate_counting_for_children.pdf
  87. https://www.mayoclinic.org/diseases-conditions/hyperglycemia/symptoms-causes/syc-20373631
  88. https://www.mayoclinic.org/diseases-conditions/hypoglycemia/symptoms-causes/syc-20373685
  89. http://www.lillydiabetes.com/_assets/pdf/ld90766_carbguide.pdf

  • Recent Post